Worst Stock Ever

Discussion in 'Neogenomics' started by Anonymous, Feb 21, 2011 at 7:36 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    NeoGenomics shares should be bought on weakness, says Ladenburg
    After NeoGenomics' stock retreated, Ladenburg believes that investors are confused about the impact of changes to the billing process of technical components under Medicare. The firm believes that the changes are unlikely to derail the company's strong growth, and it reiterates a Buy rating. :theflyonthewall.com


    So to get our price to not fall we will say the following:

    However, we are disappointed that anticipated changes in the TC Grandfather Clause will now require us to concentrate on changing our billing practices rather than on improving cancer genetic testing.

    Like you guys are the be all and end all in "Discovery" !! How arogant and untrue...
     

  2. Anonymous

    Anonymous Guest

    the best way to turn $100.00 into 10 dollars is to buy this stock. We are the Hindenburg
     
  3. Anonymous

    Anonymous Guest

    And Neo knows this so as a stock holder I get a letter begging me to write my congress person about extending the clause.

    This letter is scary, do you think clients realize that its a little Self-Serving?

    Ugh
     
  4. Anonymous

    Anonymous Guest

    I think I can, I think I can, I know I can, I know I can, ohhhh no I can't, oh no I can't...........

    Break through the $1.80 @ share price....
     
  5. Anonymous

    Anonymous Guest

    Oh My God!! Trading this stock this week has been like watching the waves in Hawaii!!

    1.65 -> 1.75 -> 1.54-> 1.68 -> 1.51->1.65

    What is one employee buying and another selling the same shares. I am going to put in a bid and get the heck OUT!!
     
  6. Anonymous

    Anonymous Guest

    Hey, not so bad now!!

    Thanks Clarient...Your helping us more than you will EVER know!!!!

    First Quarter 2012 Highlights:
    75% test volume growth
    72% revenue growth
    85% gross profit growth
    Adjusted EBITDA of $1.8 million versus $(97,000) in Q1 2011
    Net income of $603,000, or $0.01 per share, versus a net loss of ($893,000), or ($0.02) per share, in Q1 2011
     
  7. Anonymous

    Anonymous Guest

    Hey Neo. with Abbott getting sued, I guess they have no more money to spend on you.

    If they are smart they will sell of their 10% and use it to put $12.50 towars their 1.5 billion fine!!
     
  8. Anonymous

    Anonymous Guest



    if you're TRADING this stock, you like the volatility....you noob!
     
  9. Anonymous

    Anonymous Guest

    $ 2.15 !
    Interesting ...espeacily since the trade volume is so low that it is obvious that Neo Employees ARE buying and selling each other.